MedPath

Network Meta-Analysis to Evaluate PARP Inhibitors for Platinum-Sensitive Ovarian Cancer

• A network meta-analysis protocol has been developed to compare the efficacy and side effects of PARP inhibitors in platinum-sensitive ovarian cancer. • The study will analyze randomized, double-blind, phase III trials of Niraparib, Rucaparib, Olaparib, and Veliparib. • Primary outcomes include progression-free survival and overall survival, while secondary outcomes focus on grade ≥3 treatment-emergent adverse events. • The analysis aims to identify the preferred PARP inhibitor based on efficacy and safety profiles, addressing a critical question in ovarian cancer treatment.

A systematic review and network meta-analysis protocol has been developed to evaluate the efficacy and safety of various PARP (poly-ADP ribose polymerase) inhibitors in patients with platinum-sensitive ovarian cancer. The study aims to address the question of which PARP inhibitor should be preferred in this setting, considering both efficacy and side effects.

Methods and Design

The network meta-analysis will include randomized, double-blind, controlled phase III trials of Niraparib, Rucaparib, Olaparib, or Veliparib in patients with platinum-sensitive ovarian cancer. Data will be sourced from PubMed, Embase, the Cochrane Library, ClinicalTrials.gov, and the World Health Organization (WHO) International Clinical Trials Registry Platform from 1990 to 2023.
The primary outcomes of interest are progression-free survival (PFS) and overall survival (OS). Secondary outcomes will focus on treatment-emergent adverse events of grade ≥3. Statistical analyses will be performed using STATA V.14.0 and RevMan software to assess the risk of bias. The quality of evidence will be determined using the GRADEpro GDT software.

Significance and Limitations

PARP inhibitors have demonstrated efficacy in treating patients with platinum-sensitive ovarian cancer, improving progression-free survival and overall survival. However, comprehensive evidence comparing different agents is lacking. This network meta-analysis seeks to provide a comparative assessment of these agents.
The study acknowledges that network meta-analyses do not carry the same weight of evidence as direct head-to-head trials. However, they serve as a valuable complementary method when direct comparative studies are not feasible. Trials involving platinum-resistant or refractory ovarian cancer will be excluded from the analysis.
The results of this systematic review and network meta-analysis are intended for publication in peer-reviewed scientific journals, conferences, and the mass media. This study is registered on the PROSPERO international prospective Register of Systematic Reviews (PROSPERO CRD42024511248).
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Niraparib Shows Promise in Extending Progression-Free Survival in Epithelial Ovarian Cancer

Niraparib monotherapy extends real-world progression-free survival (rwPFS) and time to next treatment (rwTTNT) in patients with epithelial ovarian cancer (EOC).
Patients with homologous recombination-deficient (HRd) tumors, particularly those with BRCA-mutated tumors, experienced longer rwPFS and rwTTNT.

Olaparib/Cediranib Combination Fails to Improve Survival in Relapsed Ovarian Cancer

The phase 3 ICON9 trial investigated olaparib plus cediranib versus olaparib alone as maintenance therapy for relapsed platinum-sensitive ovarian cancer.
The combination of olaparib and cediranib did not significantly improve progression-free survival compared to olaparib monotherapy (HR = 0.84; 95% CI, 0.65-1.07; P = .24).

Targeted Therapies Show Promise in High-Grade Serous Ovarian Cancer Treatment

Traditional treatments for high-grade serous ovarian cancer, involving surgery and platinum-based chemotherapy, often lead to resistance, necessitating targeted therapies.
PARP inhibitors and anti-angiogenic agents like bevacizumab have improved upfront therapy, but other targeted approaches, including immunotherapy, have shown limited success.

Next-generation PARP Inhibitor Shows Promise in Treating HRR-Deficient Breast Cancer

Saruparib, a selective PARP1 inhibitor, has demonstrated significant clinical benefits in patients with homologous recombination repair (HRR)-deficient breast cancer, showing a promising objective response rate and progression-free survival. The drug's higher selectivity for PARP1 improves safety and tolerability, allowing for higher doses and potentially better efficacy.

PARP Inhibitors Show Promise in Ovarian Cancer Maintenance Therapy

PARP inhibitors, particularly olaparib, niraparib and rucaparib, demonstrate efficacy as maintenance therapy for newly-diagnosed and recurrent platinum-sensitive epithelial ovarian cancer (EOC).
These inhibitors significantly improve progression-free survival (PFS), but their impact on overall survival (OS) remains uncertain due to immature data.

Comparative Analysis of PARP Inhibitors in BRCA-Mutated Ovarian Cancer Shows Similar Efficacy and Toxicity

A network meta-analysis of PARP inhibitors (PARPi) in BRCA-mutated ovarian cancer reveals no significant differences in efficacy among various regimens used in upfront or relapsed settings.
The study assesses the cost-effectiveness of PARPi regimens using the ASCO value framework, indicating similar clinical benefits, toxicity, and net health benefit across different treatments.

PARP Inhibitors Show Similar Efficacy in BRCA-Mutated Ovarian Cancer, Cost-Effectiveness Varies

A network meta-analysis reveals no significant differences in efficacy among PARP inhibitor regimens for BRCA-mutated ovarian cancer patients in upfront or relapsed settings.
The ASCO value framework suggests similar clinical benefits and toxicity profiles across PARP inhibitor regimens in both upfront and relapsed settings.

PARP Inhibitors in Frontline Ovarian Cancer Treatment: A Review of Clinical Trials

Frontline PARP inhibitor maintenance shows greatest benefit in patients with BRCA-associated ovarian cancers, followed by those with homologous recombination deficient (HRD) tumors.
Key factors in deciding on frontline PARP inhibitor therapy include FDA indication, dosing preference, toxicity profiles, patient-specific risk-benefit assessment, and cost considerations.

PARP Inhibitors Show Promise in Epithelial Ovarian and Breast Cancers with BRCA1/2 Mutations

PARP inhibitors have demonstrated efficacy in platinum-sensitive epithelial ovarian cancer, particularly in high-grade serous disease, and in breast cancer with BRCA1/2 mutations.
Olaparib maintenance therapy significantly improved progression-free survival in relapsed high-grade serous ovarian cancer, especially in patients with BRCA1/2 mutations.

Niraparib Maintenance Therapy Demonstrates Sustained Benefit in Recurrent Ovarian Cancer

Niraparib maintenance therapy significantly improves progression-free survival (PFS) in patients with recurrent, platinum-sensitive ovarian cancer, regardless of BRCA mutation status.
The NOVA trial, a phase 3 study, demonstrated a statistically significant and clinically meaningful benefit with niraparib compared to placebo in prolonging time to disease progression.

Reference News

[1]
Olaparib Leads PARP Inhibitors in Boosting OS for Platinum-Sensitive Recurrent Ovarian Cancer
ajmc.com · Feb 3, 2025
[2]
Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian ... - Frontiers
frontiersin.org · Jan 6, 2025

A systematic review and network meta-analysis protocol to compare PARP inhibitors (Niraparib, Rucaparib, Olaparib, Velip...

[3]
Real-World Study Highlights PARP Inhibitor Challenges in Ovarian Cancer Care
ajmc.com · Jan 23, 2025

Nearly half of advanced ovarian cancer patients on first-line PARP inhibitor maintenance relapsed, highlighting the need...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy